Fig. 8

HLJDD inhibited NF-κB and ERK pathway on CAL-27 and SCC-25. A CAL-27 cells were treated with HLJDD 5 mg/mL, HLJDD 2.5 mg/mL, HLJDD 1.25 mg/mL, paclitaxel 6 μg/mL and cisplatin 5 μg/mL for 24 h. We detected the expression of p-NF-κB p65 (S468), NF-κB p65, p-ERK1/2 and p-IKK α + β by using the western blot analysis. The statistics were expressed as Mean ± SEM, n = 3. *** p < 0.001, **p < 0.01, * p < 0.05 vs. control group. B SCC-25cells were treated with HLJDD 5 mg/mL, HLJDD 2.5 mg/mL, HLJDD 1.25 mg/mL, paclitaxel 6 μg/mL and cisplatin 5 μg/mL for 24 h. We detected the expression of p-NF-κB p65 (S468), NF-κB p65, p-ERK1/2 and p-IKK α + β by using the western blot analysis. The statistics were expressed as Mean ± SEM, n = 3. *** p < 0.001, **p < 0.01, * p < 0.05 vs. control group